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Abstract 
Colorectal cancer is a serious complication associated with inflammatory bowel disease, often 
indistinguishable by screening with conventional FDG PET probes. We have developed an alter-
native EGFR-targeted PET imaging probe that may be used to overcome this difficulty, and suc-
cessfully assessed its utility for neoplastic lesion detection in preclinical models. Cetuximab F(ab′)2 
fragments were enzymatically generated, purified, and DOTA-conjugated. Radiolabeling was 
performed with 
67Ga for cell based studies and 
64Cu for in vivo imaging. Competitive binding studies 
were performed on CT26 cells to assess affinity (KD) and receptors per cell (Bmax). In vivo imaging 
using the EGFR targeted PET probe and 
18F FDG was performed on CT26 tumor bearing mice in 
both control and dextran sodium sulfate (DSS) induced colitis settings. Spontaneous adenomas in 
genetically engineered mouse (GEM) models of colon cancer were additionally imaged. The EGFR 
imaging agent was generated with high purity (> 98%), with a labeling efficiency of 60 ± 5% and 
≥99% radiochemical purity. The KD was 6.6 ± 0.7 nM and the Bmax for CT26 cells was 3.3 ± 0.1 × 10
6 
receptors/cell. Target to background ratios (TBR) for CT26 tumors compared to colonic uptake 
demonstrated high values for both 
18F-FDG (3.95 ± 0.13) and the developed 
64Cu-DOTA-cetuximab-F(ab′)2 probe (4.42 ± 0.11) in control mice. The TBR for the EGFR tar-
geted probe remained high (3.78 ± 0.06) in the setting of colitis, while for 
18F FDG, this was 
markedly reduced (1.54 ± 0.08). Assessment of the EGFR targeted probe in the GEM models 
demonstrated a correlation between radiotracer uptake in spontaneous colonic lesions and the 
EGFR staining level ex vivo. A clinically translatable PET imaging probe was successfully developed 
to assess EGFR. The imaging agent can detect colonic tumors with a high TBR for detection of in 
situ lesions in the setting of colitis, and opens the possibility for a new approach for screening 
high-risk patients. 
Key words: Positron emission tomography (PET) imaging, molecular imaging, EGFR, ulcerative 
colitis, colorectal cancer, mouse models. 
Introduction 
Inflammatory bowel disease (IBD), which con-
sists of Crohn’s  disease (CD) and ulcerative colitis 
(UC), is a chronic inflammatory condition that results 
from dysregulation of the mucosal immune system in 
the gastrointestinal tract1. The incidence of IBD is in-
creasing, and 1.4 million people in the United States 
and 2.2 million people in Europe are affected by the 
disease2. Colorectal cancer (CRC) is one of the most 
serious complications of IBD involving the colon, and 
is responsible for 10-15% of IBD deaths. CRC is cura-
ble at the early stages and early detection of CRC or 
colonic adenomas resulting from chronic inflamma-
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tion is a major focus of current research studies to 
improve patient survival3. Endoscopic guided biopsy 
is the standard for the diagnosis of CRC and periodic 
colonoscopy examinations reduces the mortality risk 
in IBD-associated CRC4. However, the issues sur-
rounding endoscopic screening are exacerbated in 
ulcerative colitis (UC), in which dysplasia can develop 
in macroscopically normal-appearing mucosa5. Cur-
rent colonoscopic surveillance in UC patients relies on 
random biopsies throughout the colon, which is a 
relatively insensitive and cumbersome strategy that is 
not widely utilized6. Because periodic screening is 
essential to reduce the incidence of IBD-associated 
CRC, the development of better molecular imaging 
technologies to detect CRC in the setting of colitis 
could provide a new approach for screening in this 
setting.  
Positron emission tomography (PET) is of con-
siderable importance to clinicians in the staging and 
treatment planning in patients with CRC7. 
18F-Fluorodeoxyglucose (FDG) is a glucose analog 
that is the most widely employed PET radioligand in 
oncology, given the increased glycolysis rate often 
observed in tumors. However, inflammatory cells are 
also glycolytically active8, and 18F FDG has been used 
to monitor the degree of active inflammation in 
IBD8-10. Improved differentiation between neoplastic 
and nonneoplastic lesions is important in target selec-
tion for molecular imaging11. Detection of the in-
creased glycolytic activity of CRC in the setting of 
increased glycolytic activity seen in IBD may result in 
a poor target to background ratio (TBR) for 18F-FDG.  
We hypothesized that highly expressed epitopes 
on CRC tumor cells may provide an alternative target 
for imaging in this setting. We noted that epidermal 
growth factor receptor (EGFR) overexpression is pre-
sent in approximately 80% of CRC cases, correlated 
with poor prognosis, decreased survival, and early 
recurrence12. While EGFR overexpression by itself 
does not directly result in utility as a therapeutic tar-
get, based in part on downstream K-RAS and addi-
tional signaling requirements13, the high rate of over-
expression may be exploited as a target for lesion de-
tection14. Inflammatory cell lineages do not overex-
press EGFR, and thus in the setting of colitis, imaging 
based on EGFR expression may result in high TBR for 
detection of in situ cancer15. We developed a novel 
EGFR targeted PET imaging agent and tested the 
probe to assess radioligand uptake in colon cancer 
allografts, spontaneous colonic adenomas in genet-
ically engineered mouse models, and in chemically 
induced colitis. We compared the TBR for allografts 
and colitis for the EGFR targeted probe relative to 
18F-FDG.  
Materials and Methods 
Preparation of F(ab′)2 fragments 
Cetuximab F(ab′)2 fragments were prepared by 
specific enzymatic digestion using a FragIT Micro-
Spin column (Genovis, Lund, Sweden) and the crude 
digest was purified by an immobilized NAb Protein 
A spin column (ThermoScientific Sci, Rockford, IL, 
USA) to remove the Fc fragment. The purity of ce-
tuximab-F(ab′)2 was assessed with sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS- 
PAGE) on a 4-15% Mimi-PROTEAN TGX mini-gel 
(Bio-Rad, Mississauga, ON, Canada) and with fast 
protein liquid chromatography (FPLC). F(ab′)2 was 
electrophoresed under non-reducing conditions with 
SDS-PAGE and the gel was stained with Bio-Safe 
Coomassie G-250 stain (Bio-Rad, Mississauga, ON, 
Canada). FPLC was performed on a HIPREP 26/60 
Sephacryl  S-200 HR column (GE Healthcare 
Bio-Sciences AB, Björkgatan, Uppsala, Sweden) and 
eluted with 100 mM NaH2PO4  buffer (pH 7.0) at a 
flow rate of 1.2 mL/min at 280 nm. Trace metals were 
removed from all buffers using Chelex-100 cati-
on-exchange resin (Sigma-Aldrich, Saint Louis, MO, 
USA). Cetuximab-F(ab′)2 fragments were concen-
trated and buffer-exchanged into 0.1 M HEPES buffer, 
pH 8.9 on an Amicon Ultracel 30 K device (MWCO= 
30 kDa; EMD Millipore Corporation, Billerica, MA, 
USA)16. Cetuximab-F(ab′)2 was conjugated with the 
bifunctional  2-(4-isothiocyanatobenzyl)-1,4,7,10- 
tetraazacyclodo-decane-1,4,7,10-tetraacetic acid 
(p-SCN-Bn-DOTA, Macrocyclics, Inc., Dallas, TX, 
USA) chelate in anhydrous DMSO by a modification 
of established methods using 10 fold molar excess of 
chelate to cetuximab  F(ab′)217, 18. Conjugation was 
allowed to proceed  overnight  at  2−8  °C. 
DOTA-cetuximab-  F(ab′)2 was purified from excess 
DOTA by the Amicon Ultracel 30 K device with 0.25 
M ammonium acetate buffer (pH 6.0) and centrifug-
ing at 3500 rpm for 10 min. This purification step was 
repeated six times. Finally, purified DOTA- 
cetuximab-F(ab′)2 was recovered and the concentra-
tion determined spectrophotometrically [E280 nm = 
1.45 (mg/mL)-1 cm-1]19. The final concentration was 
adjusted with 0.25 M ammonium acetate buffer (pH 
6.0) for aliquoting. 
The DOTA substitution level of the F(ab′)2 
fragments (chelators/molecule) was measured by 
labeling a 10 µL aliquot of the unpurified conjugate 
with  67Ga and then determining the proportion of 
67Ga-DOTA-cetuximab-F(ab′)2 vs. free 67Ga-DOTA by 
ITLC-SG and multiplying this fraction by the molar 
ratio used in the reaction19.  Theranostics 2014, Vol. 4, Issue 9 
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Radiolabeling procedures 
Radiolabeling was done with 67Ga (MDS- 
Nordion, Kanata, Canada) or 64Cu (University of 
Wisconsin, Madison, WI) as described previously20, 21. 
We used 67Ga for cell binding assays due to its rela-
tively longer half-life (3.26 d) in comparison with 64Cu 
(0.529 d) and lower energy, facilitating the cell study 
workflow. Briefly the 67Ga radioisotope (1−5 mCi) was 
added to the conjugate (50-100  µg) dissolved in 10 
mM sodium acetate buffer (pH 4.5) and then incu-
bated at 40°C for 90 min. 64Cu radiolabeling was per-
formed by incubating 50-100 µg of DOTA-cetuximab- 
F(ab′)2 in 0.25 M ammonium acetate buffer (pH 6.0) 
with 64CuCl2 for 90 min at 40°C with constant shaking. 
The  67Ga/64Cu-radiolabeled compounds were puri-
fied from free 67Ga /64Cu and other low molecular 
weight impurities on an Amicon Ultracel 30 K device. 
The purity of the labeled compounds were checked by 
size exclusion chromatography using a PD-10 De-
salting Column (GE Healthcare Bio-Sciences AB, 
Björkgatan, Uppsala, Sweden) eluting with phos-
phate-buffered saline (PBS) as the mobile phase. The 
two different isotopes were used for in vivo and in 
vitro studies, in order to more closely match the iso-
tope  half-lives  with the differences in length of the 
respective studies.  
Cell culture 
CT26 murine colorectal carcinoma and HCT-116 
human colorectal carcinoma were obtained from the 
American Type Culture Collection (ATCC). They 
were cultured in RPMI and McCoy’s 5a Medium 
(ATCC) and supplemented with 10% (v/v) fetal bo-
vine serum (FBS), 100 U/mL penicillin, and 100 
µg/mL streptomycin respectively. The cells were 
maintained in a humidified atmosphere of 5% CO2 at 
37 °C. 
Competitive binding studies 
The EGFR binding affinity of 67Ga-DOTA- 
cetuximab-F(ab′)2 was determined by direct (satura-
tion) radioligand binding assays in triplicate using a 
fixed concentration of cetuximab and increasing con-
centration of 67Ga-DOTA-cetuximab-F(ab′)2 on the 
CT26 cell line with slight modification of previous 
studies22. Briefly, increasing concentrations (0 to 100 
nmol/L) of 67Ga-DOTA-cetuximab-F(ab′)2 was incu-
bated with 1 X 105 cells in 24-well plates at 4°C for 3 
hr. Unbound radioactivity was removed and the 
dishes were rinsed three times with ice cold PBS and 
cells detached with 0.05% trypsin. The number of cells 
in each well was counted using an automated cell 
counter (Countess®, Invtrogen, NY, USA) and the 
total cell-bound radioactivity (TB) was measured in a 
gamma counter (Wizard 2480, Perkin Elmer, MA, 
USA). The assay was repeated in the presence of 16 
µmol/L of unlabeled cetuximab to measure 
non-specific binding (NSB) at 4°C for 2h. Specific 
binding (SB) was calculated by subtracting NSB from 
TB and was plotted vs. the concentration of 
67Ga-DOTA-cetuximab-F(ab′)2 added. The resulting 
curve was fitted by non-linear regression to a one-site 
receptor-binding model by Prism software 
(GraphPad, San Diego, CA, USA). The dissociation 
constant (KD) and maximum number of receptors per 
cell (Bmax) was calculated.  
Western Blot Analysis  
In order to ensure EGFR expression in CT26 and 
HCT-116 cells, Western blot analysis was carried out 
as previously described23. EGFR expression level of 
CT26 was compared with the high EGFR expressing 
HCT116 human colon cancer cell line. Briefly, EGFR 
and beta-actin were detected with EGFR receptor XP 
rabbit mAb (Cell Signaling, Danvers, MA, USA) 
(1:1000 dilution) and beta-actin rabbit mAb (Cell Sig-
naling, Danvers, MA, USA) (1:1000 dilution). Then the 
proteins were incubated with goat anti-rabbit 
IgG-HRP (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA) and detected using the BM chemilumines-
cence Western blotting kit (Roche Diagnostics, Indi-
anapolis, IN, USA) and bands were visualized with a 
Kodak  in vivo  FX PRO system (Carestream Health, 
New Haven, CT, USA).  
Animal models 
All animal experiments were approved by our 
Institutional Animal Care Committee. Mice were 
maintained with free access to standard chow and 
water. Female BALB/c mice (6 weeks old, with a body 
weight of 18-20 g) were purchased from Charles River 
Laboratories International Inc. Dextran Sulfate So-
dium (DSS)-treated mice were prepared by the ad-
ministration of 3.0% DSS (mol wt 40,000–50,000, MP 
Affymetrix, Inc., Cleveland, Ohio, USA.) in drinking 
water for seven days, followed by a regimen of three 
days of normal drinking water, as described previ-
ously24. Control mice received water ad libitum. Fresh 
DSS solutions were prepared daily and mice were 
recorded daily for the body weight loss, which was 
calculated relative to day 0. Subcutaneous (s.c) CT26 
tumors were established in a subset of BALB/C mice 
by s.c injection of 100 µL (106 cells) of CT26 cell sus-
pension in Matrigel (BD Biosciences, Franklin Lakes, 
NJ, USA) in the right upper flank.  
To further assess the imaging method, mice with 
conditional knockout (CKO) mutant alleles were 
generated as previously described25, 26,  27, 28  and 
ApcCKOp53flox/flo  and  ApcLoxP/ LoxPMsh2null/LoxP  mutant 
mouse models were used to evaluate the imaging  Theranostics 2014, Vol. 4, Issue 9 
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potential of 64Cu-DOTA-cetuximab-F(ab′)2 in CRC.  
PET/CT imaging protocol 
Before imaging with 18F-FDG, the mice were kept 
fasted for 4 hr and allowed free access to water. For 
PET/CT imaging, approximately 400 µCi of 18F-FDG 
or 100 µCi of 64Cu-DOTA-cetuximab-F(ab′)2 in a final 
volume of 200 µl was injected to each mouse via the 
tail vein under 2% isoflurane gas anesthesia.  
PET data were acquired using a whole-body 
emission protocol on an Argus small-animal PET/CT 
scanner (Sedecal, Madrid, Spain) for 15 min in 2 bed 
positions 1 hr after 18F-FDG and 24 hr after 
64Cu-DOTA-cetuximab-F(ab′)2 injection under gas 
anesthesia with 1.5% isoflurane. Images were recon-
structed with a 2D ordered-subset expectation maxi-
mization (2D-OSEM) algorithm (2 iterations, 16 sub-
sets, with scatter and randoms corrections). CT data 
were acquired in standard resolution. The scan pa-
rameters were set as follow: tube voltage 40 kVp, tube 
current 140 µA, number of projections 360, number of 
shots 8, axial field-of-view 80 mm. Scans were rec-
orded without respiratory gating. Total scan duration 
was approximately 14 min. Image data were recon-
structed using FeldKemp algorithm. 
Three-dimensional regions of interest (ROI) were 
manually drawn around tumors based on 
co-registered CT scans acquired immediately after 
PET imaging. Mean standardized uptake values 
(SUVs) were calculated within the ROI.  
Antibody blocking studies 
Blocking studies were carried out to evaluate 
EGFR specificity of 64Cu-DOTA-cetuximab-F(ab′)2 in 
vivo. Mice bearing CT26 allografts (n=4) were each 
intravenously injected with 1.5 mg of cetuximab 24 hr 
before  64Cu-DOTA-cetuximab-F(ab′)2 administration. 
The control group mice with CT26 allografts (n=4) 
were injected with intravenous PBS 24 hr before 
64Cu-DOTA-cetuximab-F(ab′)2 injection. 64Cu-DOTA- 
cetuximab-F(ab′)2 was intravenously injected into 
each mouse under isoflurane anesthesia and static 
PET/CT scans were acquired at 24 hr post injection. 
Mean standardized uptake values (SUVs) of the allo-
grafts were calculated and compared between groups.  
PET/CT imaging with 18F-FDG and 64Cu- 
DOTA-cetuximab-F(ab′)2  
PET was performed to quantitate the effect of 
intestinal inflammation upon bowel 18F-FDG uptake, 
as measured in BALB/c mice induced with DSS. 
18F-FDG was purchased from IBA. A baseline 18F-FDG 
PET/CT was performed on day 0 to ensure that the 
subject mice have no baseline bowel pathology that 
enhanced glucose uptake. 
The DSS-treated (n=4) and control mice (n=4) 
with CT26 s.c allografts were imaged with 18F-FDG 
and  64Cu-DOTA-cetuximab-F(ab′)2 PET/CT and tu-
mor to bowel ratios were compared between the 
DSS-treated mice and control group for both radio-
tracers (18F-FDG and 64Cu-DOTA-cetuximab-F(ab′)2 ). 
Conditional knockout mice with ApcCKOp53flox/flox 
and  ApcLoxP/ LoxPMsh2null/LoxP  mutation underwent 
whole body PET/CT imaging 24 hr after intravenous 
64Cu-DOTA-cetuximab-F(ab′)2 injection. The colons of 
the mice were extracted immediately after whole 
body PET/CT and were placed in the PET/CT scan-
ner for ex vivo imaging. The static ex vivo PET/CT 
images from these colons were overlaid on the gross 
white light photographs of the colons in the same 
position and orientation. 
Histological analysis 
Mice were euthanized and the colons were re-
moved, and cleaned in physiological saline solution to 
remove fecal residue. They were fixed in neutrally 
buffered 10% formalin at room temperature for 48 hr 
before they were embedded in paraffin and sectioned. 
All tissues were stained with hematoxylin and eosin 
(H&E) for histological evaluation. Light microscopy 
was performed with an Olympus IX51 microscope.  
Immunohistochemical (IHC) analysis was per-
formed on CT26 tumor allografts, and colon tissue 
samples as described previously1, 7. Briefly, unstained 
5  µm sections were cut, deparaffinized and rehy-
drated by standard techniques before antigen retriev-
al in EDTA buffer. The samples were then incubated 
in a 1:50 dilution of anti-EGFR rabbit polyclonal IgG 
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, 
USA) overnight at 4 °C. The sections were washed in 
TBST and incubated with biotinylated goat anti-rabbit 
IgG (H+L) (Abcam, Cambridge, MA, USA) for 1 hr. 
The staining was developed using the DAKO Liquid 
DAB + substrate chromogen system (Dako, 
Carpinteria, CA, USA) for 1 min. Slides were washed 
in water and counterstained with hematoxylin and 
dehydrated before mounting.  
Statistics 
Statistical analysis was performed using Prism 
software (Graphpad, San Diego, USA). Differences in 
uptake of the tracers were tested for significance using 
the t-test. P-values of 0.05 were considered significant. 
Data are represented as mean ± standard error of the 
mean (SEM). 
Results 
Radiotracer preparation and characterization 
F(ab′)2 fragment of cetuximab was produced 
through enzymatic digestion as shown in Figure 1A.  Theranostics 2014, Vol. 4, Issue 9 
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F(ab′)2 was generated with high purity (> 98%) and 
1.2 mg F(ab′)2 was recovered from 2 mg of antibody 
(~60% yield). The size-exclusion FPLC and 
SDS-PAGE results demonstrated that pure F(ab′)2 
fragment of cetuximab was obtained after the diges-
tion of intact IgG with enzymatic digestion and fol-
lowed by protein A purification (Figure 1B&C). 
Whole antibody appears at 180 min, while F(ab′)2 
appears at 202 min and Fc appears at 235 min (Figure 
1B). Reaction of cetuximab F(ab′)2 with a 10-fold ex-
cess of p-SCN-Bn-DOTA resulted in substitution of 
approximately 1 DOTA chelate per F(ab′)2. The la-
beling efficiency for 64Cu-DOTA-cetuximab-F(ab′)2 
was  60  ±  5%  and  with  ≥99%  radiochemical  purity 
(Figure 1D). The specific activity of 64Cu-DOTA- 
cetuximab-F(ab′)2 was 19.5 ± 6.8 mCi/mg cetuximab. 
We observed that CT26 murine colon cancer cell 
line has high EGFR expression, comparable to that of 
high EGFR expressing HCT-116 human colorectal 
cancel line as shown in Western blot analysis (Figure 
1F). Direct (saturation) radioligand binding assays 
showed that  64Cu-DOTA-cetuximab-F(ab′)2 bound 
specifically to EGFR on CT26 cells (Figure 1E). The KD 
value for 64Cu-DOTA-cetuximab-F(ab′)2 was 6.6 ± 0.7 
nM and the Bmax value on CT26 cells was 3.3 ± 0.1 × 106 
receptors/cell. A representative competitive binding 
curve of 64Cu-DOTA-cetuximab-F(ab′)2 is shown in 
Figure 1E.  
The 64Cu-DOTA-cetuximab-F(ab′)2 is specific 
for EGFR in vivo 
The specificity of 64Cu-DOTA-cetuximab-F(ab′)2 
for EGFR was confirmed by in vivo blocking studies 
(Figure 2). Administering a blocking dose of cetuxi-
mab the tumor uptake was significantly reduced 
(SUV of 0.31 ±  0.04 (non-blocking) vs. 0.15 ±  0.02 
(blocking), n=4; P<0.05) and (tumor to muscle SUV of 
6.64 ± 0.85 (non-blocking) vs. 2.56 ± 1.87 (blocking), 
n=4;  P<0.05) which demonstrated that 64Cu-DOTA- 
cetuximab-F(ab′)2 maintained EGFR specificity in vi-
vo.  
 
Figure 1. A schematic overview of the EGFR targeted PET probe synthesis and characterization. (A) Enzymatic fragmentation of whole antibody and conjugation of F(ab’)2 
fragment with bifunctional chelator. (B) FPLC chromatograms of whole IgG before digestion, after digestion, and after protein A purification. (C) SDS-PAGE analysis of enzymatic 
digestion of cetuximab IgG. (i) Whole antibody before digestion; (ii) F(ab’)2 and Fc bands after digestion of whole antibody; (iii) F(ab’)2 band after protein A purification. (D) 
Radiolabeling and purification of F(ab’)2-DOTA conjugate with 67Ga. (E) Direct (saturation) radioligand binding to CT26 murine colorectal cancer cells of 
64Cu-DOTA-cetuximab-F(ab’)2, in the absence (total binding; TB) or presence (non-specific binding; NSB) of excess (x 20 times) unlabeled cetuximab IgG. Specific binding (SB) 
was calculated by subtraction of NSB from TB. Curves were fit to a 1-site receptor-binding model. = TB; = NSB; = SB. (F) Western blot of EGFR expression in CT26 and 
HCT-116 colon cancer cell lines with beta-actin as control, demonstrate EGFR overexpression.  Theranostics 2014, Vol. 4, Issue 9 
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Figure 2. PET imaging of EGFR expression in BALB/c mice at 24 hr post injection of 64Cu-DOTA-cetuximab-F(ab′)2 or 64Cu-DOTA-cetuximab-F(ab’)2 after treatment with a 1.5 
mg blocking dose of cetuximab. A) Example images without and with blocking. Red circles highlight site of implanted CT26 tumor allograft B) Comparison of MeanSUV values of 
64Cu-DOTA-cetuximab-F(ab′)2 without and with blocking. Each bar represents SUVmean ± SEM; n=4 for each group, and the symbol * denotes P<0.05. C) Comparison of tumor 
to muscle ratios of 64Cu-DOTA-cetuximab-F(ab′)2 without and with blocking. Each bar represents SUVmean ± SEM; n=4 for each group, and the symbol * denotes P<0.05. 
 
The DSS induced colitis model 
Body weight loss was used to monitor colitis. 
The body weight loss gave a peak on day 8 (Figure 
3A). The body weight was significantly decreased 
(23.35 ± 0.11 g (day 0) vs. 20.45 ± 0.64 g (DSS-treated, 
day 8) and 23.35 ±  0.11 g (day 0) vs. 20.35 ±  0.21 
(DSS-treated, day 10), n=4, P<0.05) after DSS treat-
ment. PET imaging was performed on control and 
DSS-treated mice to assess the effects of colitis on 
18F-FDG colonic uptake after DSS treatment. The ar-
rows on the images indicate the high characteristic 
accumulation of 18F-FDG in the inflamed areas of 
DSS-treated mice (Figure 3B). 18F-FDG PET/CT scans 
showed significant increase in uptake (0.22 ± 0.02 
%ID/g (control) vs. 0.43 ± 0.09 %ID/g (DSS-treated, 
day 9), n=4, P<0.05) in the colons of the DSS-treated 
groups.  
Histological examination of the normal colon 
showed normal mucosal architecture. Mucin loss, loss 
of crypt architecture and intraepithelial inflammation 
was observed in the colon of mice that received DSS 
treatment for seven days (Figure 3C).  
PET/CT imaging 
In a subset of control and DSS-treated BALB/C 
mice implanted with CT26 allografts imaging was 
performed sequentially with both 18F-FDG and 
64Cu-DOTA-cetuximab- F(ab′)2 to compare the tumor 
to bowel radiotracer uptake ratios (Figure 4A). The 
tumor to bowel ratio was significantly decreased (3.95 
± 0.13 (control) vs. 1.54 ± 0.08 (DSS-treated), n=4, 
P<0.05) in DSS-treated mice imaged with 18F-FDG. 
However there was no significant difference (4.42 ± 
0.11 (control) vs. 3.78 ± 0.06 (DSS-treated), n=4, 
P=0.22) in the tumor to bowel ratio between the con-
trol and the DSS-treated mice imaged with 64Cu- 
DOTA-cetuximab-F(ab′)2.  64Cu-DOTA-cetuximab- 
F(ab′)2 also showed significantly higher (3.78 ± 0.06 
(64Cu-DOTA-cetuximab-F(ab′)2) vs. 1.54 ±  0.08  Theranostics 2014, Vol. 4, Issue 9 
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(18F-FDG), n=4; P<0.05) tumor to bowel ratio in com-
parison with 18F-FDG in DSS-induced mice (Figure 
4B). 
64Cu-DOTA-cetuximab-F(ab′)2 whole body 
PET/CT images of mice with ApcCKOP53flox/flox  and 
ApcLoxP/ LoxPMsh2null/LoxP mutations revealed focal areas 
of high uptake in colonic adenomas. After the 
PET/CT imaging, the colons were excised and im-
aged ex vivo with PET/CT. An anatomic correlation 
between the location of visible adenoma foci and are-
as of high uptake in ex vivo 64Cu-DOTA- 
cetuximab-F(ab′)2 PET/CT images was noted. (Figure 
5A&B).  
 
 
Histopathologic analysis 
H&E and IHC stained tissue sections of mice are 
shown in Figure 6. Normal colonic mucosa with crypt 
architecture, along with modulation seen with 
DSS-treatment, and characteristic features in the ad-
enomas are noted (Figure 6A). Membranous brown 
staining of cells above the background level was de-
fined as EGFR positive. IHC staining for EGFR re-
vealed very weak staining in control and DSS-treated 
colonic tissue, while strong EGFR staining was ob-
served with CT26 allograft and colon tumors from 
ApcCKOp53flox/flox  and  ApcLoxP/ LoxPMsh2null/LoxP  mutant 
mice (Figure 6B). Interestingly, the level of IHC 
staining for EGFR for the adenomatous lesions visu-
ally corresponds with the level of vivo 
64Cu-DOTA-cetuximab-F(ab′)2 uptake in the ex vivo 
samples (Figure 5).  
 
Figure 3. Assessment of symptoms and histological findings of DSS-treated and control mice. BABL/c mice were subjected to 3% DSS for seven days and followed with normal 
drinking water for three days. (A) Body weight changes following DSS induction of colitis, reported as mean ± SEM (n=4 mice/group) and the symbol * denotes P<0.05. (B) 
microPET-CT scans were obtained before and after DSS treatment. Before DSS treatment, PET showed only low level of physiologic 18F-FDG uptake in the colon of healthy 
controls. In contrast, on day nine, clearly elevated 18F-FDG colonic uptake is noted (red arrow). (C) Histological appearance of the normal colonic mucosa of healthy controls 
with intact crypts and architecture (control) and DSS-induced colitis showing inflammatory infiltration (arrow head), mucin loss (arrow) and crypt architectural disarray (dashed 
arrow). Magnification x20 and scale bar represents 100 µm.  Theranostics 2014, Vol. 4, Issue 9 
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Figure 4. Comparison of PET imaging with 18F-FDG and 64Cu-DOTA-cetuximab-F(ab′)2 in CT26 tumor-bearing mice with and without DSS-induced colitis. (A) PET-CT images 
were performed 1 hr after 18F-FDG and 24 hr after 64Cu-DOTA-cetuximab-F(ab’)2 administration. Representative images from a mouse are shown, with n=4 mice imaged in each 
group. Red squares indicate the location of tumors and blue squares indicate location of DSS-induced colitis. (B) Comparison of tumor to colon ratios at 24 hr post-injection. Each 
bar represents SUVmean ± SEM; n=4 for each group. The symbol * denote P<0.05 and the difference is not significant (P=0.22) for 64Cu-DOTA-cetuximab-F(ab′)2. The dash line 
verifies TBR=1 (no contrast). 
 
Discussion 
Persistent inflammation in the colon seen in IBD 
is correlated with increased cell proliferation, dyspla-
sia, and the subsequent development of CRC4, 29-31. 
The mortality of IBD associated CRC has remained 
high over the last 20 years, in part due to the ap-
proximately 50% of CRC that were not detected until 
an advanced stage32. Therefore there is a clear need to 
develop new screening strategies that are more sensi-
tive and less cumbersome than current approaches for 
high-risk patients. While the noninvasive nature of 
PET scanning greatly improves tolerance, colonic in-
flammation that is a hallmark of IBD affecting the 
colon makes noninvasive screening for cancer using 
18F-FDG PET somewhat less useful in the IBD setting, 
given the known uptake of the radiotracer in inflam-
matory as well as neoplastic cells. We hypothesized 
that EGFR would be an appropriate target for imag-
ing, highlighting tumor even in the setting of colitis, 
given its high expression seen in the large majority of 
CRC, and the lack of overexpression noted in normal 
colonic mucosa and in the inflammatory cells associ-
ated with chronic colitis. We thus developed an EGFR 
targeting PET imaging agent based on the F(ab′)2 
fragment of cetuximab conjugated to the chelator 
DOTA and labeled with the radiometal 64Cu. We 
chose the F(ab′)2 fragments as the basis for the imag-
ing agent given the improved target to background 
ratio (TBR) relative to whole  antibodies33, and im-
proved pharmacokinetics for translation16, 34. The de-
veloped imaging agent is translatable for human 
studies given the high safety profile of the parent an-
tibody, and the components have all been utilized in 
prior clinical translation. PET imaging agents have an 
advantage of an extremely low mass of injection given 
the high sensitivity of PET detection, and thus a broad 
range of agents have been translated to human eval-
uation35. Finally, as new algorithms are developed for 
image reconstruction and with the introduction of 
PET-MR clinical scanners, the radiation dose associ-
ated with PET imaging continues to decrease, making 
this potential approach more appealing36. While very 
low bowel uptake was seen in these preclinical studies 
in both normal and colitis settings, given the known 
hepatic clearance, early translational studies will help 
confirm that low signal from bowel remains in the 
clinical setting.  
Monoclonal antibodies are widely used as ther-
apeutics. However, their long circulation time typi-
cally in the range of days to weeks, and the potential 
for immune response, make their use as imaging 
agents less ideal37-39. Bivalent F(ab′)2 antibody frag-
ments have a shorter blood clearance, higher tumor to 
background ratios at early time points, reduced 
non-specific distribution, and lower immunogenicity 
relative to whole antibodies, while retaining the ad-
vantage of increased affinity associated with biva-
lency16, 40. The developed imaging probe has a high  Theranostics 2014, Vol. 4, Issue 9 
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affinity of 6.6 nM for EGFR. We chose a radioisotope, 
64Cu (t1/2 = 12.7 h), that matched the pharmacokinetics 
of the F(ab′)2 antibody fragment39. We demonstrated 
that the EGFR targeting probe was able to image both 
allografts (CT26 tumors) as well as spontaneous co-
lonic adenomas in two different GEM models 
(ApcCKOp53flox/flo  and  ApcLoxP/ LoxPMsh2null/LoxP)25-28  with 
high standard uptake values (SUV). In the previous 
studies, Western blots of EGFR expression on human 
and murine cell lines showed that cetuximab strongly 
binds to the murine cell line CT2641. GEM models are 
selected to provide a platform for studying CRC from 
certain mutations such Apc and p53. ApcCKOp53flox/flo 
and ApcLoxP/ LoxPMsh2null/LoxP GEM models were selected 
for this study because Apc and Msh2 processes are 
often deranged in large numbers of CRCs in the set-
ting of IBD42, 43. The EGFR targeted probe uptake in 
spontaneous lesions in representative mouse models 
of colonic adenomas further points to the translational 
potential of this approach. Both 18F-FDG and 
64Cu-DOTA-cetuximab-  F(ab′)2 demonstrated high 
TBR for tumor uptake relative to normal colon. 
However, the EGFR targeting probe retained a high 
TBR in the setting of colitis, whereas the TBR mark-
edly decreased for 18F-FDG to approximately 1.5 in 
the setting of bowel inflammation, largely due to the 
expected increase in 18F-FDG uptake in the inflamed 
bowel.  
 
 
Figure 5. Correlation between EGFR targeted PET imaging and EGFR immunohistochemistry. (A1) PET imaging of ApcCKOP53flox/flox mouse with 64Cu-DOTA-cetuximab-F(ab′)2 
at 24 hr. (A2) The digital photograph of colon and the colon fused with the ex-vivo PET image. (A3) Corresponding EGFR expression patterns of different colon sections 
numbered in A2 are confirmed with immunohistochemistry (magnification x20). (B1) Representative images of decay corrected PET image of ApcLoxP/ LoxPMsh2null/LoxP mutant mice 
after the injection of 64Cu-DOTA-cetuximab-F(ab′)2 at 24 hr. (B2) The digital photograph of colon and the colon fused with the ex-vivo PET image. (B3) EGFR expression 
patterns of different colon sections numbered in B2 are confirmed with immunohistochemistry (magnification x20). Scale bar represents 50 µm. 
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Figure 6. H&E and IHC analysis were examined to compare the histological changes in colons from healthy, DSS-treated, GEM models and allograft (CT26 tumor). IHC results 
demonstrate that there is no significant EGFR expression in healthy and DSS-treated colons, while there is strong staining in allograft and GEM model colonic lesions. (A) 
Representative H&E tissue sections from (a1) healthy colon, (a2) DSS-treated colon, (a3) CT26 allograft, (a4) ApcCKOP53flox/flox mutant mouse colon, (a5) ApcLoxP/LoxPMsh2null/LoxP 
mutant mouse colon. (B) IHC analysis of EGFR from tissues of (b1) healthy colon, (b2) DSS-treated colon, (b3) CT26 allograft, (b4) ApcCKOP53flox/flox mutant mouse colon, (b5) 
ApcLoxP/ LoxPMsh2null/LoxP mutant mouse colon. Scale bar represents 50 µm. 
 
A large percentage of IBD-associated cancers 
have immunohistochemical positivity for EGFR and 
strong EGFR intensity has been associated with high-
er tumor staging44, 45,  46.  Our results show a strong 
correlation between whole body PET-CT 
EGFR-targeted imaging, ex-vivo EGFR-based PET 
imaging of the colon, and histopathological findings 
of the degree of EGFR expression. The visualized 
weak EGFR staining of healthy colon is likely sec-
ondary to the limited EGFR expression in the baso-
lateral surface of the colon23. We additionally con-
firmed the previously reported weak EGFR staining 
for DSS-induced colitis 47. High EGFR staining was 
clearly visualized in the CT26 allograft and colorectal 
adenomas in the GEMM. It has been previously noted 
that the mean specific EGFR intensity in neoplasia is 
approximately ten times higher than in normal mu-
cosa12. Given the high correlation between lesion 
EGFR expression and uptake of the developed 
64Cu-DOTA-F(ab′)2 PET imaging probe, the approach 
may be useful not only for detection, but also for an-
ti-EGFR treatment monitoring.  
Conclusions 
A clinically translatable 64Cu-DOTA-cetuximab- 
F(ab′)2 PET imaging probe was successfully devel-
oped to assess EGFR noninvasively. The imaging 
agent can detect colonic tumors with a high target to 
background ratio in the setting of colitis. This ap-
proach offers improved imaging characteristics com-
pared to standard 18F-FDG PET imaging for detection 
of in situ lesions in the setting of IBD, and opens the 
possibility for a new approach for screening high-risk 
patients for the development of CRC in the setting of 
colonic inflammation. 
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